Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Wu, Yunyi; Li, Yanchun; Gao, Yan; Zhang, Ping; Jing, Qiangan; Zhang, Yinhao; Jin, Weidong; Wang, Ying; Du, Jing; Wu, Gongqiang

doi:10.1016/j.biopha.2024.116132

Cited by 3 publications

(1 citation statement)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 However, the effectiveness of existing cancer treatments is concerning, as tumor cell resistance is reducing the efficacy of conventional therapies like radiotherapy and chemotherapy. 2 Additionally, refractory cancers like small cell lung cancer (SCLC), 3 triple-negative breast cancer (TNBC), 4 and pancreatic cancer 5 present significant challenges in oncology treatment due to their resistance to existing therapies. Ferroptosis, a novel iron-dependent form of programmed cell death first proposed by Dr. Brent R. Stockwell in 2012, is distinct from apoptosis, necrosis, and autophagy.…”

Section: Introductionmentioning

confidence: 99%

Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches

Luo,

Bai,

Zhang

et al. 2024

DDDT

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches

Luo,

Bai,

Zhang

et al. 2024

DDDT

View full text Add to dashboard Cite

Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy

Kapor,

Radojković,

Santibanez

2024

Acta Histochemica

View full text Add to dashboard Cite

Prognosis and treatment in acute myeloid leukemia: a comprehensive review

Debnath,

Nath

2024

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous disorder that is characterized by clonal expansion of immature "blast cells" in the bone marrow and peripheral circulation, resulting in bone marrow failure and inefficient erythropoiesis. The identification of numerous recurrent genetic mutations such as NPM1, CEBPA, and FLT3-ITD has stratified AML into favorable, intermediate, and adverse-risk groups, respectively, along with a cytogenetic profile that carries a considerably different prognosis among these groups. For post-induction treatment, cytogenetics and genetic mutation testing continue to be vital prognostic tools. Despite advancements, including an increased understanding of biology and new drug targets, the cornerstone of treatment still consists of a combination of cytarabine- and anthracycline-based regimens. The majority of patients eventually relapse and die of the disease, especially the elderly population. This review describes the prognosis of different molecular markers and the major recent advancements in the treatment of AML.

show abstract

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Cited by 3 publications

References 147 publications

Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches

Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches

Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy

Prognosis and treatment in acute myeloid leukemia: a comprehensive review

Contact Info

Product

Resources

About